JPRN-jRCT2080221783未知2 期
A phase 2, open-label study of S-6810 in patients with mycosis fungoides or Sezary syndrome
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Main inclusion criteria
- •1. Patients with mycosis fungoides or Sezary syndrome confirmed by cutaneous symptom, histopathological diagnosis or hematological evidence
- •2. Patients whose TNMB staging criterion is T1-4N0-2M0B0-2 and meet any of the following:
- •a) untreated mycosis fungoides/Sezary syndrome
- •b) at least 4 weeks after treatment for mycosis fungoides/Sezary syndrome
- •c) the effect of topical steroid, topical vitamin D3 derivatives, or ultraviolet therapy for mycosis fungoides/Sezary syndrome is stable or progressive within 4 weeks
- •3. Patients whose ECOG performance status is grade 0-2
排除标准
- •Main exclusion criteria:
- •Patients whose visceral metastasis was found by imaging evaluation within 4 weeks prior to enrollment
研究者
相似试验
已完成
2 期
A phase 2, open-label study of S-646240 in patients with age-related macular degeneration accompanied by choroidal neovascularizatioAge-related macular degenerationJPRN-UMIN000008040Shionogi & Co., Ltd.40
未知
3 期
A phase 3, open-label, extension study of S-6810 in patients with mycosis fungoides or Sezary syndromeMycosis fungoides or Sezary syndromeJPRN-jRCT2080222030SHIONOGI & CO., LTD.
进行中（未招募）
不适用
A Phase 2, Open-label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid CancerTreatment of subjects with locally advanced or metastatic thyroid cancer.MedDRA version: 6.1Level: PTClassification code 10043744EUCTR2005-001618-42-ITAMGE88
未知
2 期
Phase 2 Double-blind Study of S-525606 in Patients with Japanese Cedar Pollinosis Using an Pollen Challenge ChamberJapanese cedar pollinosisJPRN-jRCT2080222876Shionogi & Co., Ltd.
未知
2 期
A phase II confirmatory study of SMP-862 therapy in patients with type 2 diabetes mellitus who are concomitantly taking sulfonylureasJPRN-jRCT2080220089Dainippon Sumitomo Pharma Co., Ltd.